p.4 抽出テキスト

7.5.3. Assessment of symptoms ........................................................... 3573 7.5.4. Management ...................................................................................... 3573 7.6. Syndromic and metabolic cardiomyopathies ............................. 3574 7.6.1. Anderson–Fabry disease .............................................................. 3574 7.6.1.1. Definition ................................................................................... 3574 7.6.1.2. Diagnosis, clinical work-up, and differential diagnosis 3574 7.6.1.3. Clinical course, outcome, and risk stratification ....... 3574 7.6.1.4. Management ............................................................................. 3577 7.6.2. RASopathies ...................................................................................... 3577 7.6.2.1. Definition ................................................................................... 3577 7.6.2.2. Diagnosis, clinical work-up, and differential diagnosis 3577 7.6.2.3. Clinical course, management, and sudden death risk stratification .............................................................................................. 3577 7.6.2.4. Management ............................................................................. 3577 7.6.3. Friedreich ataxia .............................................................................. 3578 7.6.3.1. Definition ................................................................................... 3578 7.6.3.2. Diagnosis, clinical work-up, and differential diagnosis 3578 7.6.3.3. Clinical course, management, and risk stratification 3579 7.6.3.4. Management ............................................................................. 3579 7.6.4. Glycogen storage disorders ....................................................... 3579 7.6.4.1. Definition ................................................................................... 3579 7.6.4.2. Diagnosis, clinical work-up, and differential diagnosis 3579 7.6.4.3. Clinical course, management, and risk stratification 3579 7.6.4.4. Management ............................................................................. 3579 7.7. Amyloidosis ............................................................................................... 3579 7.7.1. Definition ........................................................................................... 3579 7.7.2. Diagnosis, clinical work-up, and differential diagnosis ..... 3579 7.7.3. Clinical course and risk stratification ..................................... 3580 7.7.4. Management ...................................................................................... 3580 7.7.4.1. Specific therapies .................................................................... 3581 8. Other recommendations .............................................................................. 3581 8.1. Sports .......................................................................................................... 3581 8.1.1. Cardiovascular benefits of exercise ........................................ 3581 8.1.2. Exercise-related sudden cardiac death and historical exercise recommendations for patients with cardiomyopathy 3582 8.1.3. Exercise recommendations in hypertrophic cardiomyopathy ........................................................................................... 3582 8.1.4. Exercise recommendations in arrhythmogenic right ventricular cardiomyopathy .................................................................... 3582 8.1.5. Exercise recommendations in dilated cardiomyopathy and non-dilated left ventricular cardiomyopathy .......................... 3582 8.2. Reproductive issues ............................................................................... 3583 8.2.1. Contraception, in vitro fertilization, and hormonal treatment ........................................................................................................ 3583 8.2.2. Pregnancy management ............................................................... 3583 8.2.2.1. Pre-pregnancy .......................................................................... 3583 8.2.2.2. Pregnancy .................................................................................. 3583 8.2.2.3. Timing and mode of delivery ............................................ 3584 8.2.2.4. Post-partum .............................................................................. 3584 8.2.2.5. Pharmacological treatment: general aspects .............. 3584 8.2.2.6. Specific cardiomyopathies .................................................. 3584 8.2.2.7. Peripartum cardiomyopathy ............................................. 3585 8.3. Recommendations for non-cardiac surgery ............................... 3585 9. Requirements for specialized cardiomyopathy units ........................ 3586 10. Living with cardiomyopathy: advice for patients ............................. 3586 11. Sex differences in cardiomyopathies ..................................................... 3587 12. Comorbidities and cardiovascular risk factors in cardiomyopathies .................................................................................................. 3587 12.1. Cardiovascular risk factors .............................................................. 3587 12.2. Dilated cardiomyopathy ................................................................... 3588 12.3. Hypertrophic cardiomyopathy ...................................................... 3588 12.4. Arrhythmogenic right ventricular cardiomyopathy .............. 3588 13. Coronavirus disease (COVID-19) and cardiomyopathies ........... 3588 14. Key messages .................................................................................................. 3588 15. Gaps in evidence ............................................................................................ 3589 16. ‘What to do’ and ‘What not to do’ messages from the Guidelines ................................................................................................................. 3591 17. Supplementary data ...................................................................................... 3595 18. Data availability statement ......................................................................... 3595 19. Author information ...................................................................................... 3595 20. Appendix ........................................................................................................... 3596 21. Acknowledgements ...................................................................................... 3597 22. References ........................................................................................................ 3597

Tables of Recommendations

Recommendation Table 1 — Recommendations for the provision of service of multidisciplinary cardiomyopathy teams ................................ 3519 Recommendation Table 2 — Recommendations for diagnostic work-up in cardiomyopathies .......................................................................... 3520 Recommendation Table 3 — Recommendations for laboratory tests in the diagnosis of cardiomyopathies ................................................ 3524 Recommendation Table 4 — Recommendation for echocardiographic evaluation in patients with cardiomyopathy ...... 3524 Recommendation Table 5 — Recommendations for cardiac magnetic resonance indication in patients with cardiomyopathy .... 3526 Recommendation Table 6 — Recommendations for computed tomography and nuclear imaging ................................................................... 3528 Recommendation Table 7 — Recommendation for endomyocardial biopsy in patients with cardiomyopathy ..................................................... 3528 Recommendation Table 8 — Recommendations for genetic counselling and testing in cardiomyopathies ............................................. 3537 Recommendation Table 9 — Recommendations for cardiac transplantation in patients with cardiomyopathy ................................... 3540 Recommendation Table 10 — Recommendation for left ventricular assist device therapy in patients with cardiomyopathy ........................ 3540 Recommendation Table 11 — Recommendations for management of atrial fibrillation and atrial flutter in patients with cardiomyopathy .... 3543 Recommendation Table 12 — Recommendations for implantable cardioverter defibrillator in patients with cardiomyopathy ................ 3545 Recommendation Table 13 — Recommendations for routine follow-up of patients with cardiomyopathy .............................................. 3546 Recommendation Table 14 — Recommendations for family screening and follow-up evaluation of relatives ....................................... 3546 Recommendation Table 15 — Recommendations for psychological support in patients and family members with cardiomyopathies .... 3549 Recommendation Table 16 — Recommendation for evaluation of left ventricular outflow tract obstruction .................................................. 3549 Recommendation Table 17 — Additional recommendation for cardiovascular magnetic resonance evaluation in hypertrophic cardiomyopathy ..................................................................................................... 3550 Recommendation Table 18 — Recommendations for treatment of left ventricular outflow tract obstruction (general measures) .......... 3553 Recommendation Table 19 — Recommendations for medical treatment of left ventricular outflow tract obstruction ....................... 3554 Recommendation Table 20 — Recommendations for septal reduction therapy ................................................................................................. 3556 Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026